Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1993 Jul;68(1):176–180. doi: 10.1038/bjc.1993.309

The control of acute cisplatin-induced emesis--a comparative study of granisetron and a combination regimen of high-dose metoclopramide and dexamethasone. Granisetron Study Group.

B Chevallier 1
PMCID: PMC1968287  PMID: 8391304

Abstract

The anti-emetic efficacy and safety of granisetron, a highly selective and potent 5-HT3 receptor antagonist, was compared with that of high-dose metoclopramide plus dexamethasone in 281 patients due to receive single-day cisplatin chemotherapy (> or = 49 mg m-2). In this single-blind, multicentre study, granisetron (40 micrograms kg-1) was administered as a single prophylactic 5-min infusion. Dexamethasone (12 mg) was administered as a 30-min infusion followed by a loading dose of 3 mg kg-1 metoclopramide. A maintenance dose of metoclopramide 4 mg kg-1 was then infused over 8 h. A single prophylactic dose of granisetron was as effective as the combination regimen in the prevention of cisplatin-induced emesis. Of 143 granisetron-treated patients, 100 (70%) were complete responders (no vomiting and no or only mild nausea) compared with 93/138 (67%) patients who received the comparator regimen. Twenty-three percent of granisetron-treated patients experienced one of more adverse events compared with 33% of patients in the comparator group. No extrapyramidal reactions were reported in the granisetron group compared with 13 in comparator-treated patients (8%). This difference was significant (P < 0.05). The commonest adverse event in the granisetron group, headache (9.8%) described by the majority of patients as mild, was significantly higher than that reported in the comparator group (3% P = 0.02). Granisetron appears to be a safe and effective agent which can be used as a single agent for the prophylaxis of cisplatin-induced emesis. The simplicity of administration, a single 5-min infusion prior to chemotherapy, and the lack of somnolence or extrapyramidal reactions offer clear advantages over the comparator combination regimen.

Full text

PDF
176

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Andrykowski M. A., Redd W. H., Hatfield A. K. Development of anticipatory nausea: a prospective analysis. J Consult Clin Psychol. 1985 Aug;53(4):447–454. doi: 10.1037//0022-006x.53.4.447. [DOI] [PubMed] [Google Scholar]
  2. Bardfeld P. A. A controlled double-blind study of trimethobenzamide, prochlorperazine, and placebo. JAMA. 1966 May 30;196(9):796–798. [PubMed] [Google Scholar]
  3. Bermudez J., Boyle E. A., Miner W. D., Sanger G. J. The anti-emetic potential of the 5-hydroxytryptamine3 receptor antagonist BRL 43694. Br J Cancer. 1988 Nov;58(5):644–650. doi: 10.1038/bjc.1988.277. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Coates A., Abraham S., Kaye S. B., Sowerbutts T., Frewin C., Fox R. M., Tattersall M. H. On the receiving end--patient perception of the side-effects of cancer chemotherapy. Eur J Cancer Clin Oncol. 1983 Feb;19(2):203–208. doi: 10.1016/0277-5379(83)90418-2. [DOI] [PubMed] [Google Scholar]
  5. Gralla R. J., Itri L. M., Pisko S. E., Squillante A. E., Kelsen D. P., Braun D. W., Jr, Bordin L. A., Braun T. J., Young C. W. Antiemetic efficacy of high-dose metoclopramide: randomized trials with placebo and prochlorperazine in patients with chemotherapy-induced nausea and vomiting. N Engl J Med. 1981 Oct 15;305(16):905–909. doi: 10.1056/NEJM198110153051601. [DOI] [PubMed] [Google Scholar]
  6. Grunberg S. M., Akerley W. L., Krailo M. D., Johnson K. B., Baker C. R., Cariffe P. A. Comparison of metoclopramide and metoclopramide plus dexamethasone for complete protection from cisplatinum-induced emesis. Cancer Invest. 1986;4(5):379–385. doi: 10.3109/07357908609017518. [DOI] [PubMed] [Google Scholar]
  7. Kris M. G., Gralla R. J., Clark R. A., Tyson L. B., Fiore J. J., Kelsen D. P., Groshen S. Consecutive dose-finding trials adding lorazepam to the combination of metoclopramide plus dexamethasone: improved subjective effectiveness over the combination of diphenhydramine plus metoclopramide plus dexamethasone. Cancer Treat Rep. 1985 Nov;69(11):1257–1262. [PubMed] [Google Scholar]
  8. Kris M. G., Gralla R. J., Clark R. A., Tyson L. B., Groshen S. Antiemetic control and prevention of side effects of anti-cancer therapy with lorazepam or diphenhydramine when used in combination with metoclopramide plus dexamethasone. A double-blind, randomized trial. Cancer. 1987 Dec 1;60(11):2816–2822. doi: 10.1002/1097-0142(19871201)60:11<2816::aid-cncr2820601137>3.0.co;2-7. [DOI] [PubMed] [Google Scholar]
  9. Kris M. G., Gralla R. J., Clark R. A., Tyson L. B., O'Connell J. P., Wertheim M. S., Kelsen D. P. Incidence, course, and severity of delayed nausea and vomiting following the administration of high-dose cisplatin. J Clin Oncol. 1985 Oct;3(10):1379–1384. doi: 10.1200/JCO.1985.3.10.1379. [DOI] [PubMed] [Google Scholar]
  10. Leventhal H., Easterling D. V., Nerenz D. R., Love R. R. The role of motion sickness in predicting anticipatory nausea. J Behav Med. 1988 Apr;11(2):117–130. doi: 10.1007/BF00848260. [DOI] [PubMed] [Google Scholar]
  11. Miner W. D., Sanger G. J. Inhibition of cisplatin-induced vomiting by selective 5-hydroxytryptamine M-receptor antagonism. Br J Pharmacol. 1986 Jul;88(3):497–499. doi: 10.1111/j.1476-5381.1986.tb10228.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Moertel C. G., Reitemeier R. J. Controlled clinical studies of orally administered antiemetic drugs. Gastroenterology. 1969 Sep;57(3):262–268. [PubMed] [Google Scholar]
  13. Morrow G. R. Prevalence and correlates of anticipatory nausea and vomiting in chemotherapy patients. J Natl Cancer Inst. 1982 Apr;68(4):585–588. [PubMed] [Google Scholar]
  14. Roila F., Boschetti E., Tonato M., Basurto C., Bracarda S., Picciafuoco M., Patoia L., Santi E., Penza O., Ballatori E. Predictive factors of delayed emesis in cisplatin-treated patients and antiemetic activity and tolerability of metoclopramide or dexamethasone. A randomized single-blind study. Am J Clin Oncol. 1991 Jun;14(3):238–242. doi: 10.1097/00000421-199106000-00010. [DOI] [PubMed] [Google Scholar]
  15. Roila F., Tonato M., Basurto C., Canaletti R., Morsia D., Passalacqua R., DiCostanzo F., Donati D., Colombo N., Ballatori E. Antiemetic activity of two different high doses of metoclopramide in cisplatin-treated cancer patients: a randomized double-blind trial of the Italian Oncology Group for Clinical Research. Cancer Treat Rep. 1985 Dec;69(12):1353–1357. [PubMed] [Google Scholar]
  16. Strain J. E. The American Academy of Pediatrics comments on the "Baby Doe II" regulations. N Engl J Med. 1983 Aug 18;309(7):443–444. doi: 10.1056/NEJM198308183090728. [DOI] [PubMed] [Google Scholar]
  17. Wilcox P. M., Fetting J. H., Nettesheim K. M., Abeloff M. D. Anticipatory vomiting in women receiving cyclophosphamide, methotrexate, and 5-FU (CMF) adjuvant chemotherapy for breast carcinoma. Cancer Treat Rep. 1982 Aug;66(8):1601–1604. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES